These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 37311277)

  • 1. Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519.
    Karaś K; Karwaciak I; Chałaśkiewicz K; Sałkowska A; Pastwińska J; Bachorz RA; Ratajewski M
    Biomed Pharmacother; 2023 Aug; 164():115002. PubMed ID: 37311277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
    Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
    Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BI6727, a polo-like kinase 1 inhibitor, synergizes with gefitinib to suppress hepatocellular carcinoma cells via a G2/M arrest mechanism.
    Zhou Q; Chen T
    Pharmazie; 2022 Sep; 77(7):230-235. PubMed ID: 36199185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
    Zhong L; Yang S; Jia Y; Lei K
    J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy.
    Wei X; Nian J; Zheng J; He Y; Zeng M
    Cancer Chemother Pharmacol; 2020 May; 85(5):949-957. PubMed ID: 32279103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
    Wang L; Chen Y; Li H; Xu Q; Liu R
    Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
    Shang R; Song X; Wang P; Zhou Y; Lu X; Wang J; Xu M; Chen X; Utpatel K; Che L; Liang B; Cigliano A; Evert M; Calvisi DF; Chen X
    Gut; 2021 Sep; 70(9):1746-1757. PubMed ID: 33144318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silibinin efficacy against human hepatocellular carcinoma.
    Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
    Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
    Zhu Y; Ke KB; Xia ZK; Li HJ; Su R; Dong C; Zhou FM; Wang L; Chen R; Wu SG; Zhao H; Gu P; Leung KS; Wong MH; Lu G; Zhang JY; Jiang BH; Qiu JG; Shi XN; Lin MC
    Mol Med; 2021 Feb; 27(1):15. PubMed ID: 33579185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
    Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
    Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
    You N; Liu W; Wang T; Ji R; Wang X; Gong Z; Dou K; Tao K
    Oncol Rep; 2012 Dec; 28(6):2091-100. PubMed ID: 22993037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
    Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
    Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
    Yang AL; Wu Q; Hu ZD; Wang SP; Tao YF; Wang AM; Sun YX; Li XL; Dai L; Zhang J
    Toxicol Appl Pharmacol; 2021 Nov; 431():115739. PubMed ID: 34619160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway.
    Moran DM; Mattocks MA; Cahill PA; Koniaris LG; McKillop IH
    J Surg Res; 2008 Jun; 147(1):23-33. PubMed ID: 17574577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
    Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
    Biochem Biophys Res Commun; 2019 Jun; 513(3):589-593. PubMed ID: 30979499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma.
    Gao C; Wang S; Shao W; Zhang Y; Lu L; Jia H; Zhu K; Chen J; Dong Q; Lu M; Zhu W; Qin L
    Front Med; 2022 Jun; 16(3):467-482. PubMed ID: 34669157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer.
    Kang MA; Kim W; Jo HR; Shin YJ; Kim MH; Jeong JH
    Int J Oncol; 2018 Aug; 53(2):703-712. PubMed ID: 29901072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemistepsin A Inhibits Cell Proliferation and Induces G0/G1-Phase Arrest, Cellular Senescence and Apoptosis Via the AMPK and p53/p21 Signals in Human Hepatocellular Carcinoma.
    Baek SY; Hwang UW; Suk HY; Kim YW
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32375410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
    J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.